Lifeline Biotechnologies, Inc. Prepares for Patent Application Filing
Business Wire "US Press Releases "
RENO, Nev.--(BUSINESS WIRE)--
Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN) today announced the Company is preparing to file a patent application covering certain advancements it has achieved as a result of its continued research and development program concerning it First Warning System(TM) a process to assist in the early detection of breast cancer.
Jim Holmes, CEO of Lifeline, said, "We have received the preliminary draft of a patent application from the Company's corporate patent counsel. The application covers certain Neural Net Based Classification of Breast Cancer with blind thermal data screening for detecting breast cancer in women. This patent will add substantially to the intellectual property of the Company in terms of protecting its ability to use the temperatures given off by the earliest and smallest breast tumors as a means of detecting breast cancer at a stage when treatment is less invasive and less costly."
Dr. Louis Keith, Lifeline's Medical Director stated, "The new technology represents a refinement designed to minimize the likelihood of false positive results with the First Warning System(TM)."
Share Exchange, Series B Convertible Preferred for Common Shares
The cut-off date for the previously announced exchange of series B preferred stock for common stock, for shareholders to submit their common shares to Lifeline's Transfer Agent, OTC Corporate Stock Transfer, Jericho, NY, has been extended to May 18, 2007. The exchange is for one share of preferred, valued at $1.00 each for each 1600 shares of common stock submitted. The value of the common stock is $.000625 per share, a premium over the current market price. To qualify for the exchange, shareholders must submit a minimum of 100,000 common shares. The Series B Preferred Stock is valued at $1.00 per share for future conversion purposes. The Company will be sending an Information Statement disclosing the terms and conditions of the exchange. In addition, particulars concerning the exchange will be posted on Lifeline's website www.lbtn.com.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. has recently reacquired the First Warning System(TM) which it had sold in 2006. The Company will focus on completing the development of the First Warning System(TM), designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System(TM) is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year. The potential savings could reach $2.8 billion annually. Additionally, the First Warning System(TM) could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion. Upon successful completion of the development of the First Warning System(TM), conducting clinical trials and obtaining FDA pre-marketing clearance, Lifeline will commence marketing its breast cancer early detection system. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually. More information is available at the Company's website: www.lbtn.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
To automatically receive instant updates, press releases, and other information on this and other Big Apple Consulting USA companies, please visit www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple ComPro.
Source: Lifeline Biotechnologies, Inc.
IP: Logged |
Business Description: Medical Product Development with focus on assisted Breast Cancer Detection Systems; Business Development and Diversification with a focus on Alternate Energy.
Primary State of Incorporation: Nevada
Country of Incorporation: USA Year of Incorporation 1994
Officers: Jim Holmes, CEO/Treasurer; Louis Keith, Vice President/Secretary; Fred Schiemann, Controller/Asst. Secret/Asst. Treasurer
Fiscal Year End: December 31
Edgar Filing Status: Non EDGAR Filer
Sedar Filing Status: Non SEDAR Filer
Outstanding Shares: 6,650,250,000 as of 2007-01-22
Estimated Market Cap: Not Available Authorized Shares: 9,500,000,000 as of 2007-01-22 Number of Shareholders of Record: 9,500 as of 2007-01-22
Current Capital Change: Stk. Div.=15% Ex-Date: 2006-04-11 Record Date: 2006-04-14 Pay Date: 2006-05-01
Dividends: Amount: Div: 13,000,000 Solos Com shs Pay Date: 2006-09-30 Record Date: 2006-08-18
Class Notes: Div. One sh Natures Creations, Inc. Com for each sh Com held. Rec date=6-28-99. Pay date=8-24-99 Capital Change=shs decreased by 1 for 50 split. Pay date=07/08/1998. Capital Change=shs decreased by 1 for 200 split. Pay date=5-21-03 Capital Change=shs decreased by 1 for 150 split. Pay date=10/22/2004.
Transfer Agent: OTC Corporate Transfer Service Co., Hicksville, NY 11802
Press Release Source: Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. to Release Initial Report on First Warning's(TM) New Algorithm Tuesday May 1, 8:31 am ET
RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN - News) today announced that diagnostic success appears on the horizon for Lifeline's First Warning System(TM) which is designed to assist in the early detection of breast cancer. The company is expecting to soon release a promising initial report on its new algorithm developed by its study group. ADVERTISEMENT
Louis Keith, MD, PhD, Lifeline's Medical Director and Vice President, stated that on their recent visit to SE Asia, he and Jim Holmes, Lifeline's CEO, met with two eminent scientists of a prestigious technical university, engineers in the field of pattern recognition. These engineers, associated with Lifeline during the last three years, are assisting the Company in the development of new neural networks and have been working with the process to eliminate noise for the patient thermal data recorded by the First Warning System(TM). Thus far, the preliminary results have produced much better results in terms of reducing false positive and false negative interpretations.
Jim Holmes stated, "The Company's next step is to examine a larger group of women to verify what we have discovered."
Share Exchange, Series B Convertible Preferred for Common Shares
The cut-off date, for the previously announced exchange of series B preferred stock for common stock, for shareholders to submit their common shares to Lifeline's Transfer Agent, OTC Corporate Stock Transfer, Jericho, NY, has been extended to May 18, 2007. The exchange is for one share of preferred, valued at $1.00 each for each 1600 shares of common stock submitted. The value of the common stock is $.000625 per share, a premium over the current market price. To qualify for the exchange, shareholders must submit a minimum of 100,000 common shares. The Series B Preferred Stock is valued at $1.00 per share for future conversion purposes. The Company will be sending an Information Statement disclosing the terms and conditions of the exchange. In addition, particulars concerning the exchange will be posted on Lifeline's website www.lbtn.com.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. has recently reacquired the First Warning System(TM) which it had sold in 2006. The Company will focus on completing the development of the First Warning System(TM), designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System(TM) is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year providing a potential savings of up to $2.8 billion annually. Additionally, the First Warning System(TM) could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually. Upon successful completion of the development of the First Warning System(TM), conducting clinical trials and obtaining FDA pre-marketing clearance, Lifeline will commence marketing its breast cancer early detection system. More information is available at the Company's website: www.lbtn.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
To automatically receive instant updates, press releases, and other information on this and other Big Apple Consulting USA companies, please visit www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple ComPro.
Contact: Lifeline Biotechnologies, Inc. Rodney Marvel, Investor Relations, 1-866-THE-APPL(E) www.lbtn.com
-------------------------------------------------------------------------------- Source: Lifeline Biotechnologies, Inc.
Email Story Set News Alert Print Story
Related Quote LBTN.PK 0.00 0.00 News View Detailed Quote Delayed 20 mins Providers - Disclaimer
Related News Stories · Lifeline Biotechnologies, Inc. Prepares for Patent Application Filing - Business Wire (Mon Apr 30) · CORRECTING and REPLACING Lifeline Biotechnologies, Inc. Extends Stock Exchange Date - Business Wire (Fri Apr 27) · Lifeline Biotechnologies, Inc. Extends Stock Exchange Date - Business Wire (Thu Apr 26) · Lifeline Biotechnologies, Inc. Authorizes Stock Exchange Program to Shareholders - Business Wire (Thu Apr 5) More...
ADVERTISEMENT
Reno 911: Miami The Number 23
The Messengers Ghost Rider
The Astronaut Farmer Breach
Top Stories · Stocks Head for Moderately Higher Open - AP (8:09 am) · Procter & Gamble Earnings Rise 14 Pct. - AP (8:36 am) · Archer Daniels Midland Profit Rises - AP (8:08 am) · Sirius Satellite Radio 1Q Loss Shrinks - AP (8:03 am) More...
Lifeline Biotechnologies, Inc. Enters Negotiations for Final Phase of First Warning System(TM) Development Wednesday May 2, 8:35 am ET
RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN - News) today announced that it has entered into final negotiations for the final development of the computer software system, the related technology is the basis for its First Warning System(TM). The First Warning System(TM) is designed to assist in the early detection of breast cancer.
Jim Holmes, Lifeline's CEO stated, "We are in the final stages of negotiation with a major southeast Asian based university to complete development of the software technology which provides the capability of the Company's First Warning System(TM) to assist in the early detection of breast cancer. Lifeline has been working with engineers at the university for several years on an informal basis and a contract for a formal arrangement will be concluded. The software development is expected to be completed near term. Upon completion of the development involving the analysis of approximately 100 to 150 patient data from women previously tested using Lifeline's First Warning System(TM), additional clinical testing will be undertaken in order to validate this cutting edge technology. To date, the development has indicated a potential breakthrough in identifying breast cancer and the false positives and false negatives have been within acceptable levels."
Share Exchange, Series B Convertible Preferred for Common Shares
The cut-off date, for the previously announced exchange of series B preferred stock for common stock, for shareholders to submit their common shares to Lifeline's Transfer Agent, OTC Corporate Stock Transfer, Jericho, NY, has been extended to May 18, 2007. The exchange is for one share of preferred, valued at $1.00 each for each 1600 shares of common stock submitted. The value of the common stock is $.000625 per share, a premium over the current market price. To qualify for the exchange, shareholders must submit a minimum of 100,000 common shares. The Series B Preferred Stock is valued at $1.00 per share for future conversion purposes. The Company will be sending an Information Statement disclosing the terms and conditions of the exchange. In addition, particulars concerning the exchange will be posted on Lifeline's website www.lbtn.com.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. has recently reacquired the First Warning System(TM) which it had sold in 2006. The Company will focus on completing the development of the First Warning System(TM), designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System(TM) is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year providing a potential savings of up to $2.8 billion annually. Additionally, the First Warning System(TM) could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually. Upon successful completion of the development of the First Warning System(TM), conducting clinical trials and obtaining FDA pre-marketing clearance, Lifeline will commence marketing its breast cancer early detection system More information is available at the Company's website: www.lbtn.com.
IP: Logged |
posted
barbara... where in NC are you from - Charlotte HERE... anywho - This used to go up and down from 1 to 2 all day long and has been dead for a long time. I am holding a few million shares and hope all of this is true!
IP: Logged |
posted
Diluting hurts in several ways 1) It causes the pps to drop quickly. In this case it just stays at bottom. 2) It eliminates buyers that would have paid a higher price. Everyone now get it cheap, so that leaves no new buyers to bring the price up again. 3) This scares away new investors that would have bought in. 4) It's an indication that the company is in financial trouble. 5) It means the company leaders just don't know what they are doing.
The sad thing is that all companies do this even the major players. The difference is that the betters companies do it in small chunk when things are looking good, so it goes unnoticed. The struggling companies do it because they either need the cash to fund and finish their project or they are in financial trouble and need the cash to prevent from going under. Worst case is that they are a scam from the start and they only make money by issuing shares and R/S and repeating the process.
I think LBTN is using it to fund their research, so that a good thing unless it goes on too long.
IP: Logged |
posted
Yep. i think you're right about dilluting. Just about all of these small companies do this junk. They need money to pay of all other things.
IP: Logged |
posted
Wow! Volume over 1.2Bil today. They must be making good progress on the breast cancer detection software. Huge trades today some over 100Mil probably major investors getting in. Somebody knows something, so next week is going to be exciting as it moves above .0001.
IP: Logged |
quote:Originally posted by TopRob: Wow! Volume over 1.2Bil today. They must be making good progress on the breast cancer detection software. Huge trades today some over 100Mil probably major investors getting in. Somebody knows something, so next week is going to be exciting as it moves above .0001.
Outstanding Shares: 6,650,250,000 as of 2007-01-22
Estimated Market Cap: Not Available Authorized Shares: 9,500,000,000 as of 2007-01-22 Number of Shareholders of Record: 9,500 as of 2007-01-22
Current Capital Change: Stk. Div.=15% Ex-Date: 2006-04-11 Record Date: 2006-04-14 Pay Date: 2006-05-01
Dividends: Amount: Div: 13,000,000 Solos Com shs Pay Date: 2006-09-30 Record Date: 2006-08-18
Class Notes: Div. One sh Natures Creations, Inc. Com for each sh Com held. Rec date=6-28-99. Pay date=8-24-99 Capital Change=shs decreased by 1 for 50 split. Pay date=07/08/1998. Capital Change=shs decreased by 1 for 200 split. Pay date=5-21-03 Capital Change=shs decreased by 1 for 150 split. Pay date=10/22/2004.
Transfer Agent: OTC Corporate Transfer Service Co., Hicksville, NY 11802
IP: Logged |
posted
I bought $50 worth last month just for the heck of it ,, lot of volume every day but no movement and no one on bid for a while , I think there where a few MMs on bid a few days back but they are in and out... Might round out to 1 mil shares just in case it does run in the future , you never know when some of these will come off .0001.. And $100 investment, might just have fun with it ..
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
